Jessica Fye
Stock Analyst at JP Morgan
(4.51)
# 299
Out of 5,140 analysts
216
Total ratings
64.71%
Success rate
14.88%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiates: Overweight | $30 | $18.90 | +58.73% | 1 | Feb 3, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $20.19 | +28.78% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $34.29 | -27.09% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $11.36 | +102.46% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $172.19 | +15.57% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $70.98 | -8.42% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $49.87 | -49.87% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $110.15 | +8.95% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $336.19 | +40.69% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $18.12 | +319.43% | 4 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $89 | $101.32 | -12.16% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $64.08 | +85.71% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $225.00 | +17.33% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $476.90 | +11.13% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $362.14 | +6.31% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $83.15 | -3.79% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $43.44 | +19.71% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $105.16 | -26.78% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $31.91 | +9.68% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $164.91 | -18.14% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $473.42 | -30.29% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $7.45 | +74.50% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $32.75 | +52.67% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $34.79 | -13.77% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $73.73 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $10.93 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $3.48 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $15.59 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.76 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.47 | +376.19% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.20 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.51 | - | 1 | Feb 8, 2018 |
Aktis Oncology
Feb 3, 2026
Initiates: Overweight
Price Target: $30
Current: $18.90
Upside: +58.73%
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $20.19
Upside: +28.78%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $34.29
Upside: -27.09%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $11.36
Upside: +102.46%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $172.19
Upside: +15.57%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $70.98
Upside: -8.42%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $49.87
Upside: -49.87%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $110.15
Upside: +8.95%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $336.19
Upside: +40.69%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $18.12
Upside: +319.43%
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $101.32
Upside: -12.16%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $64.08
Upside: +85.71%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $225.00
Upside: +17.33%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $476.90
Upside: +11.13%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $362.14
Upside: +6.31%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $83.15
Upside: -3.79%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $43.44
Upside: +19.71%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $105.16
Upside: -26.78%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $31.91
Upside: +9.68%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $164.91
Upside: -18.14%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $473.42
Upside: -30.29%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $7.45
Upside: +74.50%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $32.75
Upside: +52.67%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $34.79
Upside: -13.77%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $73.73
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $10.93
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $3.48
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $15.59
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.76
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.47
Upside: +376.19%
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $9.20
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $13.51
Upside: -